Development and Evaluation of In-situ gel containing Linezolid and Diclofenac Sodium in the treatment of Periodontitis

Abstract

Periodontal treatment aims at reduction of infection and inflammation. Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic and anaerobic bacteria susceptible organisms methicillin and vancomycin-resistant in the treatment of periodontitis. Diclofenac sodium is anti-inflammatory agent and in-situ gel containing Linezolid and Diclofenac sodium in this study may have a potential additive effect. Hence, there is broad scope for research in local application of antimicrobial and anti-inflammatory combination drug (s) in periodontitis. Linezolid and Diclofenac sodium. In-situ gel containing Linezolid in combination with Diclofenac sodium was prepared using combination of carbopol-HPMC and carbopol-NaCMC. The prepared in-situ gel formulation showed satisfactory results for in-vitro gelling capacity, rheology, and other physical properties. In-vitro drug release profile was dependent up on the concentration of polymer, i.e. drug release was decreased with increase in polymer concentration and vice versa. The formulations of batches LDCF1, LDCF2, LDCF3, LDSF1, LD SF2 and LDSF3 failed to extend the drug release up to 12 hours. Thus, the formulation of batches LDCF4 and LDSF4 containing carbopol: HPMC and carbopol: NaCMC in 1: 2 ratios were considered as optimum formulation on the basis of optimum viscosity, gelation time, gelation temperature, gelling capacity, and their capacity to extend the in-vitro drug release up to 12 hours. Hence, prepared formulations showed sustain drug release behaviour.